T-cell large granular lymphocytic leukemia (T-LGL leukemia) is a lymphoproliferative disorder in which treatment is guided by clinical need. The priority at first line is correcting the haematological consequences of the disease.
This is a first-line protocol for patients with T-cell LGL leukemia where treatment is indicated. Management is driven by clinical need — in the majority of cases, the aim is to ameliorate cytopenias.
The established first-line strategy is immunosuppression. Specific immunosuppressive agents are used at defined schedules — the complete regimen, agent selection, and decision criteria are in the full structured protocol.
The primary endpoint is haematological response — amelioration of cytopenias. Response is assessed at approximately 4 months, since the median time to response with these agents is 3–4 months. Treatment should not be terminated early due to apparent lack of efficacy before this window has elapsed.
DOI: 10.1002/hon.70076
For many years, the standard of care has been immunosuppression, with weekly methotrexate, low dose cyclophosphamide and ciclosporin remaining the first to third line treatments for most clinicians.
This suggests that we should consider low dose cyclophosphamide as initial treatment provided that there are no contraindications.
Approximately 150 patients were randomized to one of the two arms, with 73% of patients achieving a response at month 4 with cyclophosphamide compared to only 32% in the comparator arm.
The potential downside is the fact that the cyclophosphamide is given as a fixed duration therapy up to a maximum of a year to minimize risk of secondary malignancy.
Outside a clinical trial, management should be driven by a clinical need, which in the majority of cases is to ameliorate the cytopenias.
Median time to response with these agents is 3–4 months and therefore it is important not to terminate the treatment too early because of lack of efficacy.
View source ↗